Allon is focused on developing drugs that positively impact the lives of those individuals living with neurodegenerative diseases. Like its partners, the Company is dedicated to developing treatments for major neurodegenerative conditions.
Today, Allon collaborates with the National Institute of Aging, the National Institutes of Health (NIH), The Michael J. Fox Foundation for Parkinson’s Research, Alzheimer’s Drug Discovery Foundation , Tel Aviv University and TURNS (Treatment Units for Research on Neurocognition and Schizophrenia), as the Company works to advance its neurodegenerative therapeutic programs.
Allon intends to commercialize davunetide for PSP in North America and is seeking commercialization alliances outside of North America.
Allon intends to advance its Alzheimer’s disease and schizophrenia programs through strategic partnerships, and is pursuing in-licensing opportunities of clinical assets in the central nervous system area. For more information on partnering with Allon, please contact